We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Genetic Cause of Increased Leukemia Risk Identified

By LabMedica International staff writers
Posted on 12 Apr 2015
A newly discovered heritable genetic cause of acute lymphoblastic leukemia (ALL), has been pinpointed, specifically a mutation of the oncogene that encodes an E26 transformation-specific factor (ETS). More...


Insight of the gene mutation may help doctors to increase monitoring and to develop strategies to prevent the disease as there are around 30,000 cases of ALL diagnosed in the USA each year, with a majority of cases in children aged two to five years.

A large team of international scientists led by those at University of Colorado Cancer Center (Aurora, CO, USA) identified a family with autosomal dominant thrombocytopenia, high erythrocyte mean corpuscular volume (MCV) and two occurrences of B cell–precursor acute lymphoblastic leukemia (ALL). Whole-exome sequencing identified a heterozygous single-nucleotide change in ets variant 6 (ETV6), c.641C>T, encoding a p.Pro214Leu substitution in the central domain, segregating with thrombocytopenia and elevated MCV. A screen of 23 families with similar phenotypes identified two with ETV6 mutations.

One family also had a mutation encoding p.Pro214Leu and one individual with ALL. The other family had a c.1252A>G transition producing a p.Arg418Gly substitution in the DNA-binding domain, with alternative splicing and exon skipping. Functional characterization of these mutations showed aberrant cellular localization of mutant and endogenous ETV6, decreased transcriptional repression and altered megakaryocyte maturation.

The ETV6 gene provides instructions for producing a protein that functions as a transcription factor, which means that it binds to specific regions of DNA and controls the activity of certain genes. ETV6 is involved in the development of blood cells. Dissimilar to somatic mutation of the ETV6 gene, a germline mutation places a patient one step closer to the development of leukemia from birth.

Christopher C. Porter, MD, an associate professor in the Department of Pediatrics and a senior study author said, “These people are born with a broken gene and it sets them up for leukemia. It's not common in a general population, but we think it might be much more common in people who develop ALL. This study highlights this gene in the development of leukemia. By studying this mutation, we should be able to gather a better understanding of how leukemia develops.” The study was published on March 25, 2015, in the journal Nature Genetics.

Related Links:

University of Colorado Cancer Center



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.